Expression of LSD1, a downstream substrate of PRKCQ and driver of EMT, was reported to be enriched among chemotherapy-resistant triple-negative xenograft tumors and patient circulating tumor cells [17]. This evidence concerns the gene PRKCQ and neoplasm.